<DOC>
	<DOC>NCT00736879</DOC>
	<brief_summary>The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on diet and exercise alone. The safety of this treatment will also be studied</brief_summary>
	<brief_title>Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Male and females, ≥18 to ≤77 years old, with type 2 diabetes mellitus Subjects must have central laboratory prerandomization A1C ≥7.0 and ≤ 10.0% Cpeptide ≥ 1.0 ng/mL (0.34 nmol/L) Body Mass Index ≤ 45 kg/m² Must be able to perform self monitoring of blood glucose aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt;3* upper limit of normal (ULN) Serum Total bilirubin &gt;2 mg/dL (34.2 µmol/L) Creatinine kinase &gt;3* ULN Serum creatinine ≥1.50 mg/dL (133 µmol/L) for male subjects, ≥1.40 mg/dL (124 µmol/L) for female subjects Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Diabetes Mellitus, Type 2</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
</DOC>